The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Rethinking immunotherapy strategies and tumor targeting in gastric cancer
David Goldstein, MBBS, FRACP, PRCP, University of New South Wales, Sydney, Australia, comments on the limitations of current immunotherapy approaches and the need to reassess strategies for targeting gastric cancer. A more effective approach may involve understanding the complex influences within the tumor and reversing negative factors, rather than simply combining multiple immunotherapies. Anti-angiogenic approaches are also promising, but additional therapies will be needed to make a meaningful improvement in outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s very clear that that standard approach, let’s add a logical partner and let’s get a result, didn’t work. We probably need to stop, look at translational outcomes because there’s clearly a subgroup that got a major benefit for a long time. They’re a quite small subgroup. So I think we have to reconsider what type of immunotherapy would be better, two versus one...
It’s very clear that that standard approach, let’s add a logical partner and let’s get a result, didn’t work. We probably need to stop, look at translational outcomes because there’s clearly a subgroup that got a major benefit for a long time. They’re a quite small subgroup. So I think we have to reconsider what type of immunotherapy would be better, two versus one. Probably not. It’s more about strategy and it’s more about targeting and recognizing the different influences within the tumor that are negative and reversing them rather than just hammering with more and more immunotherapy. The big message is that there’s clearly some benefit to an anti-angiogenic approach but not enough. What other partner would make that a meaningful difference?
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
